MET and lung cancer: In all, 8398 (98%) were adults and 195 (2%) were children; 7865 patients (92%) were treated for lung cancer, of whom 7270 (92%) had an ALK rearrangement, 290 (4%) had an ROS1 rearrangement and 305 (4%) had another molecular abnormality, such as in RET, MET, or NTRK.